PriceTargets.com logo

Astrana Health - ASTH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $49.88
  • Forecasted Upside: 30.05%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$38.35 As of 09/15/2026 05:00 PM ET
▼ -1.25 (-3.16%)

This chart shows the closing price for ASTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astrana Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASTH

Analyst Price Target is $49.88
▲ +30.05% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Astrana Health in the last 3 months. The average price target is $49.88, with a high forecast of $65.00 and a low forecast of $37.00. The average price target represents a 30.05% upside from the last price of $38.35.

This chart shows the closing price for ASTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Astrana Health. This rating has held steady since November 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/22/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/20/2025
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
12/19/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/19/2026
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2026
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2026
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/15/2026OppenheimerInitiated CoverageOutperform$53.00
8/27/2026Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
8/10/2026Truist FinancialBoost TargetBuy ➝ Buy$47.00 ➝ $55.00
8/7/2026BarclaysBoost TargetOverweight ➝ Overweight$50.00 ➝ $53.00
7/14/2026TD CowenBoost TargetBuy ➝ Buy$45.00 ➝ $50.00
7/14/2026BTIG ResearchBoost TargetBuy ➝ Buy$50.00 ➝ $65.00
6/2/2026BTIG ResearchReiterated RatingBuy ➝ Buy$50.00
6/1/2026Weiss RatingsUpgradeHold (C-) ➝ Hold (C)
5/26/2026BarclaysUpgradeEqual Weight ➝ Overweight$37.00 ➝ $50.00
5/14/2026Truist FinancialBoost TargetBuy ➝ Buy$38.00 ➝ $47.00
5/12/2026TD CowenBoost TargetBuy ➝ Buy$35.00 ➝ $45.00
5/11/2026BarclaysBoost TargetEqual Weight ➝ Equal Weight$26.00 ➝ $37.00
5/8/2026Robert W. BairdSet Target$45.00
5/8/2026Needham & Company LLCBoost TargetBuy ➝ Buy$30.00 ➝ $41.00
5/8/2026BTIG ResearchBoost TargetBuy ➝ Buy$40.00 ➝ $50.00
4/29/2026Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
4/15/2026Robert W. BairdBoost TargetOutperform ➝ Outperform$37.00 ➝ $40.00
3/13/2026Truist FinancialBoost TargetBuy ➝ Buy$37.00 ➝ $38.00
3/11/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
2/10/2026Zacks ResearchDowngradeHold ➝ Strong Sell
2/2/2026BTIG ResearchLower TargetBuy ➝ Buy$45.00 ➝ $40.00
1/12/2026Zacks ResearchUpgradeStrong Sell ➝ Hold
12/29/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/22/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/15/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/12/2025Needham & Company LLCInitiated CoverageBuy$28.00
12/12/2025Needham & Company LLCInitiated CoverageBuy$28.00
12/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
12/1/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/25/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy
11/25/2025Jefferies Financial GroupLower TargetBuy ➝ Buy$44.00 ➝ $37.00
11/24/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/24/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$36.00 ➝ $26.00
11/17/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/11/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
11/10/2025Zacks ResearchDowngradeHold ➝ Strong Sell
11/10/2025TD CowenLower TargetBuy ➝ Buy$40.00 ➝ $35.00
11/7/2025BTIG ResearchLower TargetBuy ➝ Buy$50.00 ➝ $45.00
10/10/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/1/2025Zacks ResearchDowngradeStrong-Buy ➝ Strong Sell
4/1/2025BarclaysInitiated CoverageEqual Weight$36.00
3/18/2025Truist FinancialLower TargetBuy ➝ Buy$50.00 ➝ $46.00
3/4/2025Bank of AmericaLower TargetBuy ➝ Buy$55.00 ➝ $49.00
3/3/2025Robert W. BairdLower TargetOutperform ➝ Outperform$86.00 ➝ $50.00
2/20/2025Stifel NicolausLower TargetBuy ➝ Buy$70.00 ➝ $56.00
1/13/2025Truist FinancialLower TargetBuy ➝ Buy$59.00 ➝ $50.00
12/16/2024Macquarie InfrastructureUpgradeHold
11/13/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$67.00 ➝ $86.00
10/14/2024TD CowenInitiated CoverageBuy$66.00
10/11/2024KeyCorpInitiated CoverageSector Weight
10/3/2024BTIG ResearchBoost TargetBuy ➝ Buy$60.00 ➝ $70.00
8/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$54.00 ➝ $67.00
8/9/2024Truist FinancialBoost TargetBuy ➝ Buy$50.00 ➝ $59.00
8/1/2024Stifel NicolausBoost TargetBuy ➝ Buy$48.00 ➝ $60.00
7/11/2024Truist FinancialUpgradeHold ➝ Buy$44.00 ➝ $50.00
6/27/2024Stifel NicolausBoost TargetBuy ➝ Buy$45.00 ➝ $48.00
5/30/2024Robert W. BairdUpgradeStrong-Buy
5/30/2024Robert W. BairdInitiated CoverageOutperform$54.00
5/8/2024Stifel NicolausLower TargetBuy ➝ Buy$50.00 ➝ $45.00
3/1/2024Truist FinancialBoost TargetHold ➝ Hold$41.00 ➝ $44.00
2/26/2024Jefferies Financial GroupInitiated CoverageBuy$50.00
(Data available from 9/15/2021 forward)

News Sentiment Rating

1.27 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2026
  • 1 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/17/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2026
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2026
  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2026

Current Sentiment

  • 6 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Astrana Health logo
Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians and extenders, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients. The company was formerly known as Apollo Medical Holdings, Inc. and changed its name to Astrana Health, Inc. in February 2024. Astrana Health, Inc. was incorporated in 1985 and is headquartered in Alhambra, California.
Read More

Today's Range

Now: $38.35
Low: $38.00
High: $39.70

50 Day Range

MA: $39.83
Low: $34.13
High: $49.00

52 Week Range

Now: $38.35
Low: $18.08
High: $51.60

Volume

314,313 shs

Average Volume

526,867 shs

Market Capitalization

$2.14 billion

P/E Ratio

46.77

Dividend Yield

N/A

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Astrana Health?

The following sell-side analysts have issued stock ratings on Astrana Health in the last twelve months: Barclays PLC, BTIG Research, Jefferies Financial Group Inc., Needham & Company LLC, Oppenheimer Holdings, Inc., Robert W. Baird, TD Cowen, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ASTH.

What is the current price target for Astrana Health?

0 Wall Street analysts have set twelve-month price targets for Astrana Health in the last year. Their average twelve-month price target is $49.88, suggesting a possible upside of 25.9%. BTIG Research has the highest price target set, predicting ASTH will reach $65.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $37.00 for Astrana Health in the next year.
View the latest price targets for ASTH.

What is the current consensus analyst rating for Astrana Health?

Astrana Health currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ASTH.

What other companies compete with Astrana Health?

Other companies that are similar to Astrana Health include Hinge Health, Chemed, Hims & Hers Health, RadNet and LifeStance Health Group. Learn More about companies similar to Astrana Health.

How do I contact Astrana Health's investor relations team?

Astrana Health's physical mailing address is 1668 S. GARFIELD AVENUE 2ND FLOOR, ALHAMBRA CA, 91801. The company's listed phone number is 626-282-0288 and its investor relations email address is [email protected]. The official website for Astrana Health is www.astranahealth.com. Learn More about contacing Astrana Health investor relations.